Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations
Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease
Other news to note for March 2, 2021
Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech
Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018
"ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"
Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
Oscotec shares rebound on launch of US clinical trial
Oscotec`s acute leukemia treatment wins orphan drug status from FDA
Oscotec wins exception policy for continued R&D for new drugs
Yuhan to start phase-3 trial on lung cancer drug Lazertinib